

The Netherlands


and the Global Fund to Fight AIDS, Tuberculosis and Malaria

The long-standing partnership between the Netherlands and the Global Fund has played an important role in the fight against HIV, tuberculosis (TB) and malaria and in building a healthier and safer world.

Our partnership

The Netherlands has been a valuable partner to the Global Fund since our inception in 2002. As a member of the Global Fund Board, the Netherlands proactively contributes to shape our governance policies and priorities. The Netherlands also engages with the Global Fund at country level, representing the donor group in some Country Coordinating Mechanisms. The Global Fund also collaborates with the Dutch global health ecosystem and benefits from its expertise. Dutch academia, technical partners and civil society organizations play an active role in the implementation of Global Fund grants in many countries. The Dutch medical and pharmaceutical industries' capacities in research & development and innovation have led to fruitful procurement partnerships between the Global Fund and key Dutch suppliers of essential health commodities.

We are committing
approximately
US\$6 billion
from 2024-2026 to
strengthen health and
community systems
– the most significant
increase in this area in
our history.



Since 2002,
the Global Fund
partnership **has saved
65 million lives** and
has **cut the combined
death rate** from AIDS,
TB and malaria
by **63%**.

Investments through the Global Fund partnership yield exceptional returns

Life expectancy has increased by 24% since 2002,
from 49 years to 61 years in 15 countries in
sub-Saharan Africa. Reduced mortality from HIV, TB
and malaria account for one-half of this increase.

US\$85 billion in cost savings from HIV investments

Global Fund and partner investments have freed up
resources and capacities, helping countries to better
respond to other diseases. As of the end of 2023,
investments in HIV had freed up 1.7 billion HIV-related
hospitalization days and averted 1.4 billion outpatient
visits, generating US\$85 billion in cost savings.

Investing in health to advance broader socioeconomic development

Global Fund disbursements of US\$63 billion made
between 2002 and the end of 2023 are estimated to
have generated health gains with a monetized intrinsic
value of US\$1.2 trillion and direct productivity gains of
US\$400 billion.

Maximum value-for-money

We maintain efficiency through strong performance
frameworks for our grants and by investing in
interventions that have a demonstrated impact. We
leverage our Pooled Procurement Mechanism (PPM)
to bring prices down and improve quality through
economies of scale. Cost reductions driven by our PPM
are projected to create savings of US\$9.8 billion for the
countries where we invest between 2027 and 2029.

Priority areas of our partnership

The Netherlands' global health priorities are strongly mirrored in the Global Fund's investments and Strategy. Our core principles of partnership, country ownership, equity and transparency help us deliver far-reaching, evidence-based and sustainable impact.

Global health security

As the world's largest multilateral provider of grants for strengthening health and community systems, the Global Fund plays a major role in bolstering global health security. We invest about US\$2 billion per year in human resources for health; community systems; data systems and digital health; strengthening leadership and governance, financial management, procurement and supply systems; and surveillance. These investments are key building blocks in reinforcing pandemic preparedness and response and have been quickly mobilized by Global Fund-supported countries – including Uganda and the Democratic Republic of the Congo – to confront outbreaks like mpox.

Impact through innovation

The Global Fund seeks to accelerate access to innovative HIV, TB and malaria prevention, diagnostic and treatment tools, making them more affordable and available to the people who need them most.

Our partnership with the Dutch social enterprise Delft Imaging, which produces portable digital X-ray systems for TB diagnosis, has been instrumental in our fight against TB.

Portable X-ray machines are easily transported to places where people face an increased risk of TB and use artificial intelligence (CAD4TB) to rapidly read results, screening people for TB in seconds. Bringing these TB screening services directly to the community is a powerful tool to stop TB in its tracks: More people with TB can be found, diagnosed and referred for treatment.

Over the past three years, the Global Fund has procured more than 500 digital X-ray systems from Delft Imaging, distributing them across 20 countries.

Support for children and adolescent girls and young women

A child dies of malaria every minute. The Global Fund supports the rollout of seasonal malaria chemoprevention, which can save lives by reducing malaria cases among children by more than 70%.

Adolescent girls and young women continue to be at risk of acquiring HIV, especially in sub-Saharan Africa. In 2023, 3.9 million adolescent girls and young women were reached with Global Fund-supported HIV prevention services.

Integrating HIV, TB and malaria prevention into broader maternal, newborn and child health care is also a focus of Global Fund-supported programs. At Vihiga County Referral Hospital in Kenya, testing rates for HIV have increased by more than a third, and screenings for malaria and TB have increased by more than 164% and 117%, respectively, since these services were integrated into antenatal care in 2021.

Sustainable investments

The Global Fund takes a comprehensive approach to sustainability.

The Global Fund's co-financing approach encourages countries to commit additional domestic resources to health programs as a requirement to receive Global Fund grants. To incentivize the delivery of these co-financing commitments, at least 15% of a country's allocation (but in some cases more) becomes available if countries make sufficient commitments and fulfill these commitments. We actively support national sustainability and transition planning so that countries eventually assume full leadership of their disease responses.

We collaborate with partners such as the World Bank, the World Health Organization (WHO) and Gavi, the Vaccine Alliance (Gavi) to support countries' efforts to unify planning, budgeting and reporting processes and increase the efficiency of operational delivery of Global Fund grants.

Strength through partnership

The Global Fund works in partnership with other global health organizations to ensure our efforts are complementary, without duplication.

For instance, in line with the Lusaka Agenda, the Global Fund, Gavi and the Global Financing Facility are aligning around four workstreams – malaria, health systems strengthening, country engagement and back-office functions. A Strategic Framework also outlines our collaboration with WHO across health policies and normative guidance, advocacy and health governance, health products and innovations, and technical support and capacity building.



The Global Fund/Andrew Esiebo/Panos

Nigeria:

Investing for impact

Nigeria is the Global Fund's largest investment portfolio, with over US\$4.8 billion invested since 2002. Efforts to tackle HIV – including expanded testing, increased access to antiretroviral therapy and strengthened public awareness – have led to significant reductions in new infections and deaths. Nigeria has harnessed more effective diagnostic methods to fight TB, such as GeneXpert machines, leading to earlier detection and treatment. Malaria control has seen considerable advancements, with the distribution of millions of insecticide-treated mosquito nets, indoor residual spraying and improved access to artemisinin-based combination therapies.

But Nigeria still bears among the highest burdens of HIV, TB and malaria in the world. Global Fund grants in Nigeria support critical interventions geared toward continuing progress against HIV, TB and malaria while strengthening health systems and pandemic preparedness. This includes support for health product management, laboratory systems and monitoring & evaluation.

About the Global Fund

The Global Fund is a worldwide partnership to defeat HIV, TB and malaria and ensure a healthier, safer, more equitable future for all. We raise and invest more than US\$5 billion a year to fight the deadliest infectious diseases, challenge the injustice that fuels them, and strengthen health systems and pandemic preparedness in more than 100 of the hardest hit countries. We unite world leaders, communities, civil society, health workers and the private sector to find solutions that have the most impact, and we take them to scale worldwide. Since 2002, the Global Fund partnership has saved 65 million lives.